Seasoned Executives Join to Support AI-Driven Growth in U.S.-Based Biomanufacturing
Axio BioPharma, a next-generation biomanufacturing company using AI to transform mammalian protein production, announced the continued expansion of its advisory board with the recent addition of Patrick Haffey. He joins existing advisors Dr. Greg Bleck and Dr. Graham Brearley, forming a deeply experienced group of leaders in biologics research, development, and operations.
“We’re excited to welcome Pat to the advisory board alongside Greg and Graham,” said Justin Byers, CEO of Axio BioPharma. “Together, they bring a tremendous depth of expertise in scaling biologics manufacturing and developing strategic partnerships. Their guidance will be invaluable as we expand our AI-enabled platform and grow our operational footprint.”
Health Technology Insights: CareRev Expands Workforce Platform to Support Allied Healthcare Professionals
Dr. Greg Bleck is a biotech R&D veteran and former Vice President at Catalent Biologics. He has played a key role in the development of more than 175 biologics currently in clinical trials and holds over 20 patents. Dr. Bleck co-founded Gala Design, the precursor to Gala Biotech, and helped pioneer the GPEx cell line platform, used in the production of numerous approved therapies.
Health Technology Insights: Ouro Medicines Launches OM336 Trial for Autoimmune Cytopenias
Dr. Graham Brearley brings over 30 years of expertise in biologics process development, technology transfer, and global manufacturing operations. He has led large-scale facility expansions and served as site head at multiple biologics manufacturing sites. Throughout his career, he has overseen more than 100 M&A due diligence and integration initiatives and managed over 20 regulatory due diligence reviews and inspections across U.S. and European regulatory agencies.
Patrick Haffey, the most recent addition to the board, is a seasoned biopharmaceutical executive with two decades of experience launching and scaling GMP operations around the world. His leadership roles at Samsung Biologics and Jubilant Hollister-Stier include overseeing facility development, quality systems, and regulatory readiness. He has raised over $150 million in capital and established long-term partnerships across the industry.
These appointments underscore Axio BioPharma’s continued commitment to operational excellence and innovation as it scales its AI-powered biomanufacturing platform and supports the next generation of biologic therapies.
Health Technology Insights: Lumeris Partners with Google Cloud to Address the U.S. Primary Care Shortage
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
